C Uyttenhove
Overview
Explore the profile of C Uyttenhove including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gajewski T, Markiewicz M, Uyttenhove C
Curr Protoc Immunol
. 2008 Apr;
Chapter 20:Unit 20.4.
PMID: 18432777
This unit presents an experimental tumor model which has led to pivotal advances in tumor immunology culminating in the preclinical development of human cancer vaccines for melanoma. The model employs...
2.
Hauer A, Uyttenhove C, de Vos P, Stroobant V, Renauld J, Van Berkel T, et al.
Circulation
. 2005 Aug;
112(7):1054-62.
PMID: 16103256
Background: Interleukin-12 (IL-12) has been identified as a key inducer of a type 1 T-helper cell cytokine pattern, which is thought to contribute to the development of atherosclerosis. We sought...
3.
Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, Van Snick J, et al.
Leukemia
. 2003 Oct;
17(12):2513-6.
PMID: 14562126
Hodgkin's lymphoma (HL) is characterised by an unbalanced cytokine secretion. Many of these cytokines have been implicated in the regulation of malignant and infiltrating cells. Interleukin-9 (IL-9) has been described...
4.
Nguyen T, Bigaignon G, Markine-Goriaynoff D, Heremans H, Nguyen T, Warnier G, et al.
J Med Microbiol
. 2003 Sep;
52(Pt 10):869-876.
PMID: 12972580
The aim of this study was the analysis of the cytokine response in BALB/c mice infected with the highly virulent RH or the weakly virulent Beverley strains of Toxoplasma gondii....
5.
Grohmann U, Fallarino F, Bianchi R, Belladonna M, Vacca C, Orabona C, et al.
J Immunol
. 2001 Jul;
167(2):708-14.
PMID: 11441074
The outcome of dendritic cell (DC) presentation of tumor and/or self peptides, including P815AB (a tumor peptide of murine mastocytoma cells) and NRP-A7 (a synthetic peptide mimotope recognized by diabetogenic...
6.
Van Pel A, De Plaen E, Duffour M, Warnier G, Uyttenhove C, Perricaudet M, et al.
Cancer Immunol Immunother
. 2001 Feb;
49(11):593-602.
PMID: 11225990
The genes of the MAGE-A family code for antigens that are strictly tumor-specific and are shared by many human tumors. Melanoma patients have been immunized against these antigens and some...
7.
STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells
Demoulin J, Uyttenhove C, Lejeune D, Mui A, Groner B, Renauld J
Cancer Res
. 2000 Aug;
60(14):3971-7.
PMID: 10919676
Interleukin-9 (IL-9) is a growth factor for T cells and various hematopoietic and lymphoid tumor cells. IL-9 signaling involves activation of Janus kinase (JAK)1 and JAK3 kinases, and signal transducer...
8.
Silla S, Fallarino F, Boon T, Uyttenhove C
Eur Cytokine Netw
. 1999 Jul;
10(2):181-90.
PMID: 10400824
Immunization of cancer patients with tumor-specific antigenic peptides is currently being tested in several clinical studies. We have examined the induction of CTL responses in mice after various modalities of...
9.
Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815
Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde B
J Immunol
. 1999 Mar;
162(6):3534-40.
PMID: 10092811
Murine mastocytoma P815 induces CTL responses against at least four distinct Ags (AB, C, D, and E). Recent studies have shown that the main component of the CTL response against...
10.
Fallarino F, Uyttenhove C, Boon T, Gajewski T
Int J Cancer
. 1999 Feb;
80(2):324-33.
PMID: 9935218
The well-characterized P815 tumor model was used to optimize anti-tumor immunization approaches in mice. Tumor peptides derived from antigens P198 or P1A were targeted to antigen-presenting cells (APC) by ex...